Abdul Mannan – Breaking in Haem: Andexanet Alfa Withdrawn from US Market
Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, shared on LinkedIn:
“Breaking in Haem: Andexanet Alfa Withdrawn from US Market
A major shift in anticoagulation reversal is happening. AstraZeneca is withdrawing the BLA for Andexxa (andexanet alfa), effective Dec 22, 2025.
Why is this happening? Let us make it simple
It’s a case of “Biochemistry vs. Clinical Outcome.”
We failed to bridge the gap from Accelerated Approval (2018) to Traditional Approval.
The Data Dilemma:
Efficacy: It worked. In ANNEXA-4, it slashed anti-Factor Xa activity (e.g., Apixaban levels dropped from ~150 to ~11 ng/mL).
Safety: The ANNEXA-I trial showed a worrying signal. Thrombotic events were 14.6% with Andexanet vs 6.9% with usual care (PCC).
What now?
We return to the basics. For life-threatening bleeding on apixaban or rivaroxaban, we rely on Prothrombin Complex Concentrates (PCC).
A reminder that even ‘targeted’ antidotes must prove they don’t cause more harm than the bleeding they are trying to stop.”
More posts featuring Abdul Mannan on Hemostasis Today.
-
Aug 11, 2026, 08:20Hasan Abbas Zaheer: Strengthening Universal Access to Safe Blood in Pakistan
-
Aug 11, 2026, 08:07Nicola Pozzi: Advancing Hemostasis Through Scientific Collaboration at Hemostasis GRC
-
Aug 11, 2026, 07:50When Access to Care Changes Everything – WFH
-
Aug 11, 2026, 07:41Kevin Land: How Cellular Therapy Is Changing Transfusion Medicine
-
Aug 11, 2026, 07:35Kuldeep Singh Bhadauria: Building the Future of Hemophilia Care in India
-
Aug 11, 2026, 07:28Archil Jaliashvili: When Every Minute Matters Time Becomes a Therapy
-
Aug 11, 2026, 07:05Mavis Agnes Kisakye: Building Sustainable Transition Pathways in Hemophilia Care
-
Aug 11, 2026, 06:48Rishdha Roshad: What Happens to the Brain During Cardiopulmonary Bypass?
-
Aug 11, 2026, 05:53Isaac Okello: Strengthening Sickle Cell Advocacy in Uganda